Doxorubicin hydrochloride

• Catalog No.: Bio-0029
• CAS Number: 25316-40-9
• M. F.: C27H30ClNO11
• M. W.: 579.9802

SYNONYMS

• IUPAC name: (8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione hydrochloride
• IUPAC Traditional name: (8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione hydrochloride
• Synonyms: Adriamycin

DATABASE IDS

• CAS Number: 25316-40-9

PROPERTIES

• Application(s): Antineoplastic antibiotic
• Application(s): Shows anti-HIV activity
• Application(s): Possesses an antitumor effect against a wide spectrum of tumors
• Application(s): Used in the treatment of ovarian cancer and AIDS related Kaposi sarcoma
• Biological Source: Metab. of Streptomyces peucetius
• Salt Data: HCl
• Mechanism of Action: Forms complexes with DNA by intercalation between base pairs
• Mechanism of Action: Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes
• Mechanism of Action: May also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA

REFERENCES

• Arcamone, F. et al., Tet. Lett., 1969, 1007, (struct, ir, uv, ms, nmr)
• IARC Monog., 1976, 10, 43; Suppl. 6, 35; Suppl. 7, 82, (rev, tox)
• Smith, T.H. et al., J.A.C.S., 1976, 98, 1969, (synth)
• Arnone, A. et al., Tet. Lett., 1976, 3349, (cmr)
• Suzuki, F. et al., J.A.C.S., 1978, 100, 2272, (synth)
• Swenton, J.S. et al., J.A.C.S., 1978, 100, 6188, (synth, ir, uv, ms, nmr)
• Vigevani, A. et al., Anal. Profiles Drug Subst., 1980, 9, 245, (rev, synth, anal)
• Cassinelli, G. et al., J. Antibiot., 1980, 33, 1468; 1982, 35, 176, (derivs)
• Cassinelli, G. et al., J.A.C.S., 1980, 102, 1462, (derivs)
• Gioia, B. et al., Biomed. Mass Spectrom., 1984, 11, 35, (ms, derivs)
• White, R.J. et al., Drugs Pharm. Sci., 1984, 22, 569, (rev)
• Barranco, S.C., Pharmacol. Ther., 1984, 24, 303, (rev, pharmacol)
• Brown, J.R. et al., Prog. Med. Chem., 1984, 21, 169, (rev)
• Traganos, F. et al., Cancer Res., 1985, 45, 6273-6279; 1991, 51, 3682-3689, (AD 198)
• Acton, E.M., Drugs Exp. Clin. Res., 1985, 11, 1, (A 489, rev)
• Acton, E.M. et al., J. Med. Chem., 1986, 29, 1225, (A 489, synth)
• U.S. Pat., 1986, Univ. of Tennessee, 4 610 977; CA, 105, 209343v, (AD 198)
• Allman, T. et al., Can. J. Chem., 1987, 65, 2405, (pmr, conformn)
• Kajii, K. et al., Iyakuhin Kenkyu, 1987, 18, 704, (Pirarubicin, uv, ir, pmr, struct)
• Nakashima, H., J. Antibiot., 1987, 396, (anti-HIV activity)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 7522
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 475; 477; 497
• Barthwal, R. et al., J. Mol. Struct., 1994, 327, 201, (pmr, conformn)
• Harstrick, A. et al., Anti-Cancer Drugs, 1995, 6, 681-685, (AD 198)
• Coukell, A.J. et al., Drugs, 1997, 53, 453-482; 520-538, (Epirubicin, Doxorubicin, pharmacol, rev)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, AES750; EBB100; HKA300; COP765; DAM800